Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Size and usage patterns of private TB drug markets in the high burden countries.

Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME.

PLoS One. 2011 May 4;6(5):e18964. doi: 10.1371/journal.pone.0018964.

2.

Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.

Laing RO, McGoldrick KM.

Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S194-207. Review.

PMID:
11144553
3.

Implications of the current tuberculosis treatment landscape for future regimen change.

Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe NR.

Int J Tuberc Lung Dis. 2011 Jun;15(6):746-53. doi: 10.5588/ijtld.10.0094.

PMID:
21575293
4.

Estimate of the global market for rifampicin-containing fixed-dose combination tablets.

Norval PY, Blomberg B, Kitler ME, Dye C, Spinaci S.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S292-300; discussion S317-21.

PMID:
10593708
5.
6.

Assessment of doctors' knowledge regarding tuberculosis management in Lucknow, India: a public-private sector comparison.

Vandan N, Ali M, Prasad R, Kuroiwa C.

Public Health. 2009 Jul;123(7):484-9. doi: 10.1016/j.puhe.2009.05.004. Epub 2009 Jun 26.

PMID:
19560176
7.

Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.

Catalani E.

Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S289-91; discussion S317-21.

PMID:
10593707
8.

Understanding Market Size and Reporting Gaps for Paediatric TB in Indonesia, Nigeria and Pakistan: Supporting Improved Treatment of Childhood TB in the Advent of New Medicines.

Coghlan R, Gardiner E, Amanullah F, Ihekweazu C, Triasih R, Grzemska M, Sismanidis C.

PLoS One. 2015 Oct 13;10(10):e0138323. doi: 10.1371/journal.pone.0138323. eCollection 2015.

9.

Anti-tuberculosis treatment in private pharmacies, Kathmandu Valley, Nepal.

Hurtig AK, Pande SB, Baral SC, Porter JD, Bam DS.

Int J Tuberc Lung Dis. 2000 Aug;4(8):730-6.

PMID:
10949324
10.

Control of tuberculosis in an urban setting in Nepal: public-private partnership.

Newell JN, Pande SB, Baral SC, Bam DS, Malla P.

Bull World Health Organ. 2004 Feb;82(2):92-8. Epub 2004 Mar 16.

11.

Cost-effectiveness of treating multidrug-resistant tuberculosis.

Resch SC, Salomon JA, Murray M, Weinstein MC.

PLoS Med. 2006 Jul;3(7):e241.

12.

Multi-drug resistant tuberculosis burden and risk factors: an update.

Marahatta SB.

Kathmandu Univ Med J (KUMJ). 2010 Jan-Mar;8(29):116-25. Review.

PMID:
21209520
13.

Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.

Gemal A, Keravec J, Menezes A, Trajman A.

BMC Public Health. 2013 Mar 27;13:279. doi: 10.1186/1471-2458-13-279.

14.

Implementing a public-private mix model for tuberculosis treatment in urban Pakistan: lessons and experiences.

Naqvi SA, Naseer M, Kazi A, Pethani A, Naeem I, Zainab S, Fatmi Z.

Int J Tuberc Lung Dis. 2012 Jun;16(6):817-21. doi: 10.5588/ijtld.11.0440. Epub 2012 Apr 9.

PMID:
22507031
15.

A public-private partnership for TB control in Timika, Papua Province, Indonesia.

Ardian M, Meokbun E, Siburian L, Malonda E, Waramori G, Penttinen P, Lempoy J, Kenangalem E, Tjitra E, Kelly PM.

Int J Tuberc Lung Dis. 2007 Oct;11(10):1101-7.

PMID:
17945067
16.

Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.

Pantoja A, Lönnroth K, Lal SS, Chauhan LS, Uplekar M, Padma MR, Unnikrishnan KP, Rajesh J, Kumar P, Sahu S, Wares F, Floyd K.

Int J Tuberc Lung Dis. 2009 Jun;13(6):705-12.

PMID:
19460245
17.

Knowledge, attitudes and practices of private sector providers of tuberculosis care: a scoping review.

Bell CA, Duncan G, Saini B.

Int J Tuberc Lung Dis. 2011 Aug;15(8):1005-17. doi: 10.5588/ijtld.10.0294. Review.

PMID:
21669027
18.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
19.

Tuberculosis control and the private health sector in Bolivia: a survey of pharmacies.

Lambert ML, Delgado R, Michaux G, Volz A, Van der Stuyft P.

Int J Tuberc Lung Dis. 2004 Nov;8(11):1325-9.

PMID:
15581200
20.

Market size and sales pattern of tuberculosis drugs in the Philippines.

Islam T, van Weezenbeek C, Vianzon R, Garfin AM, Hiatt T, Lew WJ, Tisocki K.

Public Health Action. 2013 Dec 21;3(4):337-41. doi: 10.5588/pha.13.0094.

Supplemental Content

Support Center